<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> and glipizide added to <z:chebi fb="0" ids="6801">metformin</z:chebi> provided similar degrees of glycemic efficacy in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with inadequate glycemic control on <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy at 1 year; however, significantly more patients in the <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> group achieved an A1C reduction of &gt;0.5% without <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and without an increase in body weight </plain></SENT>
</text></document>